{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T09:01:24Z","timestamp":1776416484021,"version":"3.51.2"},"reference-count":70,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T00:00:00Z","timestamp":1773532800000},"content-version":"vor","delay-in-days":73,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002565","name":"Alzheimer\u2019s Drug Discovery Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002565","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001068","name":"Dana Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001068","id-type":"DOI","asserted-by":"publisher"}]},{"name":"ADM Diagnostics, Inc"},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 AG063819"],"award-info":[{"award-number":["R01 AG063819"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 AG064020"],"award-info":[{"award-number":["R01 AG064020"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Department of Defense Award","award":["AZ240200"],"award-info":[{"award-number":["AZ240200"]}]},{"DOI":"10.13039\/100003239","name":"Claire Pasarow Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003239","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Brian and Tania Higgins Charitable Foundation"},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019180","name":"European Union\u2019s Horizon Europe research","doi-asserted-by":"publisher","award":["#ALFGBG-71320"],"award-info":[{"award-number":["#ALFGBG-71320"]}],"id":[{"id":"10.13039\/100019180","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000957","name":"Strategic Fund and the Alzheimer's Association","doi-asserted-by":"publisher","award":["#ADSF-21-831376-C"],"award-info":[{"award-number":["#ADSF-21-831376-C"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000957","name":"Strategic Fund and the Alzheimer's Association","doi-asserted-by":"publisher","award":["#ADSF-21-831381-C"],"award-info":[{"award-number":["#ADSF-21-831381-C"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000957","name":"Strategic Fund and the Alzheimer's Association","doi-asserted-by":"publisher","award":["#ADSF-21-831377-C"],"award-info":[{"award-number":["#ADSF-21-831377-C"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000957","name":"Strategic Fund and the Alzheimer's Association","doi-asserted-by":"publisher","award":["#ADSF-24-1284328-C"],"award-info":[{"award-number":["#ADSF-24-1284328-C"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007625","name":"Cure Alzheimer\u2019s Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021720","name":"Olav Thon Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021720","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007436","name":"Erling-Persson Family Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018734","name":"European Union Joint Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018734","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013278","name":"Neurodegenerative Disease Research","doi-asserted-by":"publisher","award":["JPND2021-00694"],"award-info":[{"award-number":["JPND2021-00694"]}],"id":[{"id":"10.13039\/100013278","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012621","name":"University College London Hospitals Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012621","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017510","name":"UK Dementia Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017510","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000765","name":"University College London","doi-asserted-by":"publisher","award":["UKDRI-1003"],"award-info":[{"award-number":["UKDRI-1003"]}],"id":[{"id":"10.13039\/501100000765","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>While the biomarkers available for Alzheimer's disease are continually expanding, including clinically approved blood tests, not all of the relationships between various biomarkers have been fully elucidated. In this study, we explore how regional brain metabolism, as measured by fludeoxyglucose-18 (FDG)-PET, relates to plasma biomarkers such as p-tau217, Glial fibrillary acidic protein (GFAP), phosphorylated-tau (p-tau)217\/beta-amyloid (A\u03b2) 42, and A\u03b242\/40 in a cohort of participants with early symptomatic Alzheimer\u2019s disease. P-tau217 showed a consistent pattern of participants with higher p-tau217 levels having increased hypometabolism in Alzheimer\u2019s disease-related regions in neocortical association areas such as the lateral temporal cortex, the precuneus and inferior parietal cortex and atrophy accompanied by greater cognitive impairment. GFAP also related to regional hypometabolism and atrophy in regions known to be affected in Alzheimer\u2019s disease, though with a slightly different regional pattern. We additionally observed that participants with equivalent biomarker levels still exhibited diverse patterns of FDG-PET and atrophy. This suggests that, despite the above correlations, imaging provides additional information. These findings support and extend our knowledge of how plasma p-tau217 relates to other Alzheimer\u2019s disease biomarkers and cerebral metabolism, helping to contextualize both the benefits and limitations of these plasma biomarkers.<\/jats:p>","DOI":"10.1093\/braincomms\/fcag074","type":"journal-article","created":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T12:47:38Z","timestamp":1772887658000},"source":"Crossref","is-referenced-by-count":0,"title":["Plasma p-tau217 and glucose metabolism correlate in neocortical association areas in Alzheimer's disease"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2279-4510","authenticated-orcid":false,"given":"Lauren N","family":"Koenig","sequence":"first","affiliation":[{"name":"ADM Diagnostics, Inc. , Northbrook, IL 60062 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanna","family":"Huber","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg , 43180 M\u00f6lndal ,","place":["Sweden"]},{"name":"German Center for Neurodegenerative Diseases (DZNE) Bonn Department of Translational Dementia Research, , 53127 Bonn ,","place":["Germany"]},{"name":"University Hospital Bonn Clinic of Old Age Psychiatry and Cognitive Disorders, , 53127 Bonn ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8437-3899","authenticated-orcid":false,"given":"Anjalika","family":"Chongtham","sequence":"additional","affiliation":[{"name":"Department of Neurology, Icahn School of Medicine at Mount Sinai , NewYork, NY 10029 ,","place":["USA"]},{"name":"Nash Family Department of Neuroscience, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai , NewYork, NY 10029 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5339-933X","authenticated-orcid":false,"given":"Guglielmo","family":"Di Molfetta","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg , 43180 M\u00f6lndal ,","place":["Sweden"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1712-1920","authenticated-orcid":false,"given":"Randolph D","family":"Andrews","sequence":"additional","affiliation":[{"name":"ADM Diagnostics, Inc. , Northbrook, IL 60062 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Lukic","sequence":"additional","affiliation":[{"name":"ADM Diagnostics, Inc. , Northbrook, IL 60062 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5683-1026","authenticated-orcid":false,"given":"Neeva","family":"Shafiian","sequence":"additional","affiliation":[{"name":"Department of Neurology, Icahn School of Medicine at Mount Sinai , NewYork, NY 10029 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Howard M","family":"Fillit","sequence":"additional","affiliation":[{"name":"The Alzheimer's Drug Discovery Foundation , NewYork, NY 10019 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg , 43180 M\u00f6lndal ,","place":["Sweden"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas J","family":"Ashton","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg , 43180 M\u00f6lndal ,","place":["Sweden"]},{"name":"Banner Alzheimer's Institute, University of Arizona , Phoenix, AZ 85006 ,","place":["USA"]},{"name":"Banner Sun Health Research Institute , Sun City, AZ 85351 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3930-4354","authenticated-orcid":false,"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg , 43180 M\u00f6lndal ,","place":["Sweden"]},{"name":"Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison , Madison, WI 53792 ,","place":["USA"]},{"name":"Department of Neurodegenerative Disease, UCL Institute of Neurology , London WC1N 3BG ,","place":["UK"]},{"name":"Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital , M\u00f6lndal S-431 80 ,","place":["Sweden"]},{"name":"Department and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health , Madison, WI 53705-2281 ,","place":["USA"]},{"name":"UK Dementia Research Institute at UCL , London WC1E 6BT ,","place":["UK"]},{"name":"Hong Kong Center for Neurodegenerative Diseases, InnoHK , ,","place":["Hong Kong China"]},{"name":"Centre for Brain Research, Indian Institute of Science , Bangalore 560012, Karnataka ,","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0516-7470","authenticated-orcid":false,"given":"Dawn C","family":"Matthews","sequence":"additional","affiliation":[{"name":"ADM Diagnostics, Inc. , Northbrook, IL 60062 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana C","family":"Pereira","sequence":"additional","affiliation":[{"name":"Department of Neurology, Icahn School of Medicine at Mount Sinai , NewYork, NY 10029 ,","place":["USA"]},{"name":"Nash Family Department of Neuroscience, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai , NewYork, NY 10029 ,","place":["USA"]},{"name":"Sanford Grossman Interdisciplinary Program I Neural Circuitry and Immune Function, Icahn School of Medicine at Mount Sinai , NewYork, NY 10029 ,","place":["USA"]},{"name":"Ronald M. Loeb Center for Alzheimer's Disease, Icahn School of Medicine at Mount Sinai , NewYork, NY 10029 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"issue":"1","key":"2026041704023845600_fcag074-B1","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13024-019-0333-5","article-title":"The neuropathological diagnosis of Alzheimer\u2019s disease","volume":"14","author":"DeTure","year":"2019","journal-title":"Mol Neurodegener"},{"issue":"1","key":"2026041704023845600_fcag074-B2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/13872877251374353","article-title":"Neuroinflammation and Alzheimer\u2019s disease: Unravelling the molecular mechanisms","volume":"108","author":"Kakkar","year":"2025","journal-title":"J Alzheimers Dis"},{"issue":"7691","key":"2026041704023845600_fcag074-B3","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nature25456","article-title":"High performance plasma amyloid-\u03b2 biomarkers for Alzheimer\u2019s disease","volume":"554","author":"Nakamura","year":"2018","journal-title":"Nature"},{"issue":"11","key":"2026041704023845600_fcag074-B4","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1093\/brain\/awab223","article-title":"Plasma GFAP is an early marker of amyloid-\u03b2 but not tau pathology in Alzheimer\u2019s disease","volume":"144","author":"Pereira","year":"2021","journal-title":"Brain"},{"issue":"7","key":"2026041704023845600_fcag074-B5","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/s41582-022-00665-2","article-title":"Blood phospho-tau in Alzheimer disease: Analysis, interpretation, and clinical utility","volume":"18","author":"Karikari","year":"2022","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"2026041704023845600_fcag074-B6","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1038\/s41467-021-23620-z","article-title":"A multicentre validation study of the diagnostic value of plasma neurofilament light","volume":"12","author":"Ashton","year":"2021","journal-title":"Nat Commun"},{"key":"2026041704023845600_fcag074-B7","doi-asserted-by":"crossref","first-page":"r1082","DOI":"10.1136\/bmj.r1082","article-title":"FDA approves blood test to diagnose Alzheimer\u2019s","volume":"389","author":"Tanne","year":"2025","journal-title":"BMJ"},{"issue":"12","key":"2026041704023845600_fcag074-B8","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1038\/s41591-022-02074-w","article-title":"Differential roles of A\u03b242\/40, p-tau231 and p-tau217 for Alzheimer\u2019s trial selection and disease monitoring","volume":"28","author":"Ashton","year":"2022","journal-title":"Nat Med"},{"issue":"4","key":"2026041704023845600_fcag074-B9","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1038\/s41591-024-02869-z","article-title":"Highly accurate blood test for Alzheimer\u2019s disease is similar or superior to clinical cerebrospinal fluid tests","volume":"30","author":"Barth\u00e9lemy","year":"2024","journal-title":"Nat Med"},{"issue":"7","key":"2026041704023845600_fcag074-B10","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/s41591-022-01822-2","article-title":"Performance of plasma phosphorylated tau 181 and 217 in the community","volume":"28","author":"Mielke","year":"2022","journal-title":"Nat Med"},{"issue":"8","key":"2026041704023845600_fcag074-B11","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/jama.2020.12134","article-title":"Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders","volume":"324","author":"Palmqvist","year":"2020","journal-title":"JAMA"},{"issue":"1","key":"2026041704023845600_fcag074-B12","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13195-021-00804-9","article-title":"Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment","volume":"13","author":"Cicognola","year":"2021","journal-title":"Alzheimers Res Ther"},{"issue":"3","key":"2026041704023845600_fcag074-B13","doi-asserted-by":"crossref","first-page":"e12490","DOI":"10.1002\/trc2.12490","article-title":"Relationships between plasma biomarkers, tau PET, FDG PET, and volumetric MRI in mild to moderate Alzheimer\u2019s disease patients","volume":"10","author":"Matthews","year":"2024","journal-title":"Alzheimers Dement Transl Res Clin Intervent"},{"issue":"1","key":"2026041704023845600_fcag074-B14","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s13195-023-01302-w","article-title":"Head-to-head comparison between plasma p-tau217 and flortaucipir-PET in amyloid-positive patients with cognitive impairment","volume":"15","author":"Mundada","year":"2023","journal-title":"Alzheimers Res Ther"},{"issue":"3","key":"2026041704023845600_fcag074-B15","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00401-020-02195-x","article-title":"Plasma p-tau181 accurately predicts Alzheimer\u2019s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline","volume":"140","author":"Lantero Rodriguez","year":"2020","journal-title":"Acta Neuropathol"},{"issue":"5","key":"2026041704023845600_fcag074-B16","doi-asserted-by":"crossref","first-page":"e17123","DOI":"10.15252\/emmm.202217123","article-title":"Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads","volume":"15","author":"Salvad\u00f3","year":"2023","journal-title":"EMBO Mol Med"},{"issue":"4","key":"2026041704023845600_fcag074-B17","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1093\/brain\/awac333","article-title":"Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer\u2019s disease","volume":"146","author":"Janelidze","year":"2023","journal-title":"Brain"},{"issue":"8","key":"2026041704023845600_fcag074-B18","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.3390\/biomedicines12081836","article-title":"P-tau217 as a reliable blood-based marker of Alzheimer\u2019s disease","volume":"12","author":"Lai","year":"2024","journal-title":"Biomedicines"},{"issue":"11","key":"2026041704023845600_fcag074-B19","doi-asserted-by":"crossref","first-page":"8074","DOI":"10.1002\/alz.14315","article-title":"Head-to-head comparison of leading blood tests for Alzheimer\u2019s disease pathology","volume":"20","author":"Schindler","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"3","key":"2026041704023845600_fcag074-B20","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1001\/jamaneurol.2023.5319","article-title":"Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer disease pathology","volume":"81","author":"Ashton","year":"2024","journal-title":"JAMA Neurol"},{"issue":"8","key":"2026041704023845600_fcag074-B21","doi-asserted-by":"crossref","first-page":"5617","DOI":"10.1002\/alz.14073","article-title":"Plasma pTau217 predicts continuous brain amyloid levels in preclinical and early Alzheimer\u2019s disease","volume":"20","author":"Devanarayan","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"4","key":"2026041704023845600_fcag074-B22","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1007\/s00415-023-12148-5","article-title":"Head-to-head study of diagnostic accuracy of plasma and cerebrospinal fluid p-tau217 versus p-tau181 and p-tau231 in a memory clinic cohort","volume":"271","author":"Mendes","year":"2024","journal-title":"J Neurol"},{"issue":"6","key":"2026041704023845600_fcag074-B23","doi-asserted-by":"crossref","first-page":"e14022","DOI":"10.15252\/emmm.202114022","article-title":"Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau","volume":"13","author":"Mattsson-Carlgren","year":"2021","journal-title":"EMBO Mol Med"},{"key":"2026041704023845600_fcag074-B24","doi-asserted-by":"crossref","first-page":"105046","DOI":"10.1016\/j.ebiom.2024.105046","article-title":"Comparison of two plasma p-tau217 assays to detect and monitor Alzheimer\u2019s pathology","volume":"102","author":"Therriault","year":"2024","journal-title":"EBioMedicine"},{"issue":"6","key":"2026041704023845600_fcag074-B25","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1038\/s41591-025-03617-7","article-title":"Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer\u2019s disease","volume":"31","author":"Horie","year":"2025","journal-title":"Nat Med"},{"key":"2026041704023845600_fcag074-B26","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13195-022-01005-8","article-title":"Diagnostic and prognostic performance to detect Alzheimer\u2019s disease and clinical progression of a novel assay for plasma p-tau217","volume":"14","author":"Groot","year":"2022","journal-title":"Alzheimers Res Ther"},{"issue":"4","key":"2026041704023845600_fcag074-B27","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.3233\/JAD-190220","article-title":"18F-FDG is a superior indicator of cognitive performance compared to 18F-florbetapir in Alzheimer\u2019s disease and mild cognitive impairment evaluation: A global quantitative analysis","volume":"70","author":"Khosravi","year":"2019","journal-title":"J Alzheimers Dis"},{"issue":"7","key":"2026041704023845600_fcag074-B28","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.neurobiolaging.2009.07.002","article-title":"Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI","volume":"32","author":"Landau","year":"2011","journal-title":"Neurobiol Aging."},{"issue":"Suppl 1","key":"2026041704023845600_fcag074-B29","doi-asserted-by":"crossref","first-page":"2S","DOI":"10.2967\/jnumed.121.263194","article-title":"18F-FDG PET imaging in neurodegenerative dementing disorders: Insights into subtype classification, emerging disease categories, and mixed dementia with copathologies","volume":"63","author":"Minoshima","year":"2022","journal-title":"J Nucl Med"},{"issue":"10","key":"2026041704023845600_fcag074-B30","doi-asserted-by":"crossref","first-page":"e413","DOI":"10.1097\/RLU.0000000000000547","article-title":"Brain PET in the diagnosis of Alzheimer\u2019s disease","volume":"39","author":"Marcus","year":"2014","journal-title":"Clin Nucl Med"},{"issue":"5","key":"2026041704023845600_fcag074-B31","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1176\/appi.ajp.159.5.738","article-title":"Longitudinal PET evaluation of cerebral metabolic decline in dementia: A potential outcome measure in Alzheimer\u2019s disease treatment studies","volume":"159","author":"Alexander","year":"2002","journal-title":"Am J Psychiatry"},{"issue":"3","key":"2026041704023845600_fcag074-B32","doi-asserted-by":"crossref","first-page":"390","DOI":"10.2967\/jnumed.107.045385","article-title":"Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer\u2019s disease, and other dementias","volume":"49","author":"Mosconi","year":"2008","journal-title":"J Nucl Med"},{"issue":"5","key":"2026041704023845600_fcag074-B33","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1093\/cercor\/bhy078","article-title":"Relationships between tau and glucose metabolism reflect Alzheimer\u2019s disease pathology in cognitively normal older adults","volume":"29","author":"Adams","year":"2019","journal-title":"Cerebral Cortex"},{"issue":"2","key":"2026041704023845600_fcag074-B34","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1093\/brain\/awab294","article-title":"Cortical hypometabolism reflects local atrophy and tau pathology in symptomatic Alzheimer\u2019s disease","volume":"145","author":"Strom","year":"2022","journal-title":"Brain"},{"issue":"8","key":"2026041704023845600_fcag074-B35","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.jalz.2018.02.020","article-title":"Imaging correlations of tau, amyloid, metabolism, and atrophy in typical and atypical Alzheimer\u2019s disease","volume":"14","author":"Whitwell","year":"2018","journal-title":"Alzheimers Dement"},{"issue":"17","key":"2026041704023845600_fcag074-B36","doi-asserted-by":"crossref","first-page":"6010","DOI":"10.1073\/pnas.82.17.6010","article-title":"Differential effects of electrical stimulation of sciatic nerve on metabolic activity in spinal cord and dorsal root ganglion in the rat","volume":"82","author":"Kadekaro","year":"1985","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2026041704023845600_fcag074-B37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11571-007-9033-x","article-title":"The physiological and biochemical bases of functional brain imaging","volume":"2","author":"Sokoloff","year":"2008","journal-title":"Cogn Neurodyn"},{"issue":"524","key":"2026041704023845600_fcag074-B38","doi-asserted-by":"crossref","first-page":"eaau5732","DOI":"10.1126\/scitranslmed.aau5732","article-title":"Prospective longitudinal atrophy in Alzheimer\u2019s disease correlates with the intensity and topography of baseline tau-PET","volume":"12","author":"La Joie","year":"2020","journal-title":"Sci Transl Med"},{"issue":"1","key":"2026041704023845600_fcag074-B39","doi-asserted-by":"crossref","first-page":"e12106","DOI":"10.1002\/trc2.12106","article-title":"Rasagiline effects on glucose metabolism, cognition, and tau in Alzheimer\u2019s dementia","volume":"7","author":"Matthews","year":"2021","journal-title":"Alzheimers Dement (N Y)"},{"issue":"Pt 5","key":"2026041704023845600_fcag074-B40","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1093\/brain\/aww027","article-title":"Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer\u2019s disease","volume":"139","author":"Ossenkoppele","year":"2016","journal-title":"Brain"},{"issue":"12","key":"2026041704023845600_fcag074-B41","doi-asserted-by":"crossref","first-page":"3742","DOI":"10.1093\/brain\/awab222","article-title":"Riluzole, a glutamate modulator, slows cerebral glucose metabolism decline in patients with Alzheimer\u2019s disease","volume":"144","author":"Matthews","year":"2021","journal-title":"Brain"},{"issue":"5","key":"2026041704023845600_fcag074-B42","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s00401-021-02275-6","article-title":"Plasma p-tau231: A new biomarker for incipient Alzheimer\u2019s disease pathology","volume":"141","author":"Ashton","year":"2021","journal-title":"Acta Neuropathol"},{"issue":"5","key":"2026041704023845600_fcag074-B43","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","article-title":"Blood phosphorylated tau 181 as a biomarker for Alzheimer\u2019s disease: A diagnostic performance and prediction modelling study using data from four prospective cohorts","volume":"19","author":"Karikari","year":"2020","journal-title":"Lancet Neurol"},{"key":"2026041704023845600_fcag074-B44","doi-asserted-by":"crossref","DOI":"10.25080\/Majora-92bf1922-011","article-title":"Statsmodels: Econometric and statistical modeling with python","author":"Seabold","year":"2010","journal-title":"SciPy"},{"key":"2026041704023845600_fcag074-B45","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.neurobiolaging.2017.02.010","article-title":"Difference in imaging biomarkers of neurodegeneration between early and late-onset amnestic Alzheimer\u2019s disease","volume":"54","author":"Aziz","year":"2017","journal-title":"Neurobiol Aging."},{"issue":"1","key":"2026041704023845600_fcag074-B46","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s13195-024-01450-7","article-title":"Impact of amyloid and tau positivity on longitudinal brain atrophy in cognitively normal individuals","volume":"16","author":"Fujishima","year":"2024","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"2026041704023845600_fcag074-B47","doi-asserted-by":"crossref","first-page":"11557","DOI":"10.1038\/s41598-018-29937-y","article-title":"Longitudinal effects of aging on 18F-FDG distribution in cognitively normal elderly individuals","volume":"8","author":"Ishibashi","year":"2018","journal-title":"Sci Rep"},{"issue":"1","key":"2026041704023845600_fcag074-B48","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13195-018-0404-9","article-title":"Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer\u2019s disease","volume":"10","author":"Lewczuk","year":"2018","journal-title":"Alzheimers Res Ther"},{"issue":"4","key":"2026041704023845600_fcag074-B49","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1001\/jamaneurol.2020.4986","article-title":"Longitudinal associations of blood phosphorylated Tau181 and neurofilament light chain with neurodegeneration in Alzheimer disease","volume":"78","author":"Moscoso","year":"2021","journal-title":"JAMA Neurol."},{"issue":"9","key":"2026041704023845600_fcag074-B50","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S1474-4422(21)00214-3","article-title":"Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer\u2019s disease and frontotemporal lobar degeneration: A retrospective diagnostic performance study","volume":"20","author":"Thijssen","year":"2021","journal-title":"Lancet Neurol."},{"issue":"1","key":"2026041704023845600_fcag074-B51","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/alz.13454","article-title":"Plasma phosphorylated tau-217 exhibits sex-specific prognostication of cognitive decline and brain atrophy in cognitively unimpaired adults","volume":"20","author":"Saloner","year":"2024","journal-title":"Alzheimers Dement"},{"key":"2026041704023845600_fcag074-B52","doi-asserted-by":"publisher","author":"Strother S, Oder A, Spring R, Grady C.","year":"2010","DOI":"10.1007\/978-3-7908-2604-3_10"},{"key":"2026041704023845600_fcag074-B53","first-page":"164","article-title":"Enrichment factors for clinical trials in mild-to-moderate Alzheimer\u2019s disease","volume":"5","author":"Ballard","year":"2019","journal-title":"Alzheimers Dement"},{"issue":"4","key":"2026041704023845600_fcag074-B54","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00308809","article-title":"Neuropathological stageing of Alzheimer-related changes","volume":"82","author":"Braak","year":"1991","journal-title":"Acta Neuropathol"},{"issue":"8","key":"2026041704023845600_fcag074-B55","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1001\/jamaneurol.2024.1612","article-title":"Tau positron emission tomography for predicting dementia in individuals with mild cognitive impairment","volume":"81","author":"Groot","year":"2024","journal-title":"JAMA Neurol"},{"issue":"1","key":"2026041704023845600_fcag074-B56","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s13195-021-00939-9","article-title":"Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231","volume":"13","author":"Bayoumy","year":"2021","journal-title":"Alzheimers Res Ther"},{"issue":"S5","key":"2026041704023845600_fcag074-B57","doi-asserted-by":"crossref","first-page":"e057860","DOI":"10.1002\/alz.057860","article-title":"Plasma p-Tau181 and p-Tau231 offer complementary information to identify Alzheimer\u2019s disease pathophysiology","volume":"17","author":"Ferreira","year":"2021","journal-title":"Alzheimer\u2019s & Dementia"},{"issue":"8","key":"2026041704023845600_fcag074-B58","doi-asserted-by":"crossref","first-page":"e14398","DOI":"10.15252\/emmm.202114398","article-title":"Tau PET correlates with different Alzheimer\u2019s disease-related features compared to CSF and plasma p-tau biomarkers","volume":"13","author":"Ossenkoppele","year":"2021","journal-title":"EMBO Mol Med"},{"issue":"4","key":"2026041704023845600_fcag074-B59","doi-asserted-by":"crossref","first-page":"786","DOI":"10.3390\/biomedicines12040786","article-title":"Evaluating p-tau217 and p-tau231 as biomarkers for early diagnosis and differentiation of Alzheimer\u2019s disease: A narrative review","volume":"12","author":"Jarek","year":"2024","journal-title":"Biomedicines"},{"issue":"2","key":"2026041704023845600_fcag074-B60","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0006-8993(03)02361-8","article-title":"Astrocytes accumulate A beta 42 and give rise to astrocytic amyloid plaques in Alzheimer disease brains","volume":"971","author":"Nagele","year":"2003","journal-title":"Brain Res"},{"issue":"4","key":"2026041704023845600_fcag074-B61","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.neurobiolaging.2008.05.015","article-title":"Astrocyte phenotype in relation to Alzheimer-type pathology in the ageing brain","volume":"31","author":"Simpson","year":"2010","journal-title":"Neurobiol Aging"},{"issue":"1","key":"2026041704023845600_fcag074-B62","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S1474-4422(21)00361-6","article-title":"Blood-based biomarkers for Alzheimer\u2019s disease: Towards clinical implementation","volume":"21","author":"Teunissen","year":"2022","journal-title":"Lancet Neurol"},{"issue":"4","key":"2026041704023845600_fcag074-B63","doi-asserted-by":"crossref","first-page":"e12492","DOI":"10.1002\/dad2.12492","article-title":"Cross-sectional and longitudinal evaluation of plasma glial fibrillary acidic protein to detect and predict clinical syndromes of Alzheimer\u2019s disease","volume":"15","author":"Ally","year":"2023","journal-title":"Alzheimers Dement (Amst)"},{"issue":"12","key":"2026041704023845600_fcag074-B64","doi-asserted-by":"crossref","first-page":"4094","DOI":"10.1093\/brain\/awae211","article-title":"Association of glial fibrillary acid protein, Alzheimer\u2019s disease pathology and cognitive decline","volume":"147","author":"Peretti","year":"2024","journal-title":"Brain"},{"issue":"6","key":"2026041704023845600_fcag074-B65","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1017\/S1355617721000813","article-title":"Lower white matter volume and worse executive functioning reflected in higher levels of plasma GFAP among older adults with and without cognitive impairment","volume":"28","author":"Asken","year":"2022","journal-title":"J Int Neuropsychol Soc"},{"key":"2026041704023845600_fcag074-B66","doi-asserted-by":"crossref","first-page":"1461556","DOI":"10.3389\/fnagi.2024.1461556","article-title":"Elevated circulating levels of GFAP associated with reduced volumes in hippocampal subregions linked to mild cognitive impairment among community-dwelling elderly individuals","volume":"16","author":"Zhang","year":"2024","journal-title":"Front Aging Neurosci"},{"issue":"1","key":"2026041704023845600_fcag074-B67","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s13195-023-01291-w","article-title":"Different associations between amyloid-\u03b2eta 42, amyloid-\u03b2eta 40, and amyloid-\u03b2eta 42\/40 with soluble phosphorylated-tau and disease burden in Alzheimer\u2019s disease: A cerebrospinal fluid and fluorodeoxyglucose-positron emission tomography study","volume":"15","author":"Motta","year":"2023","journal-title":"Alzheimers Res Ther"},{"issue":"2","key":"2026041704023845600_fcag074-B68","doi-asserted-by":"crossref","first-page":"e70066","DOI":"10.1111\/ene.70066","article-title":"Plasma phosphorylated tau 217 as a discriminative biomarker for cerebral amyloid angiopathy","volume":"32","author":"Hsieh","year":"2025","journal-title":"Eur J Neurol."},{"issue":"3","key":"2026041704023845600_fcag074-B69","doi-asserted-by":"crossref","first-page":"e70010","DOI":"10.1002\/alz.70010","article-title":"Plasma biomarkers distinguish Boston Criteria 2.0 cerebral amyloid angiopathy from healthy controls","volume":"21","author":"Muir","year":"2025","journal-title":"Alzheimers Dement"},{"issue":"11","key":"2026041704023845600_fcag074-B70","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.jpsychires.2007.10.010","article-title":"Effects of medications on plasma amyloid beta (abeta) 42: Longitudinal data from the VITA cohort","volume":"42","author":"Blasko","year":"2008","journal-title":"J Psychiatr Res"}],"container-title":["Brain Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/braincomms\/advance-article-pdf\/doi\/10.1093\/braincomms\/fcag074\/67359694\/fcag074.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/braincomms\/article-pdf\/8\/2\/fcag074\/68101331\/fcag074.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/braincomms\/article-pdf\/8\/2\/fcag074\/68101331\/fcag074.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T08:03:25Z","timestamp":1776413005000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/braincomms\/article\/doi\/10.1093\/braincomms\/fcag074\/8524243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":70,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3,3]]}},"URL":"https:\/\/doi.org\/10.1093\/braincomms\/fcag074","relation":{},"ISSN":["2632-1297"],"issn-type":[{"value":"2632-1297","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026]]},"published":{"date-parts":[[2026]]},"article-number":"fcag074"}}